The provenge market research report is one of a series of new reports that provides provenge market statistics, including the provenge industry's global market size, regional shares, competitors with a provenge market share, detailed provenge market segments, market trends and opportunities, and any further data you may need to thrive in the provenge industry. This provenge market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the rising geriatric population, increased cancer awareness, growing demand for personalized medicine, rising research and development activities, and government initiatives. Major trends in the forecast period include innovations in immune oncology, combination therapies, product innovation, advancements in vaccine technology, and advancements in technology.
The increasing prevalence of prostate cancer is expected to contribute to the growth of the Provenge market in the coming years. Prostate cancer occurs when cells in the prostate gland begin growing uncontrollably, forming tumors that can spread to nearby tissues or other parts of the body. This rise in cases is linked to factors such as an aging population, better detection techniques, and changes in lifestyle. Provenge works by stimulating the patient's immune system to identify and attack prostate cancer cells. For example, the American Cancer Society estimates that in 2023, there will be 288,300 new cases of prostate cancer and 34,700 related deaths in the United States. As the number of prostate cancer cases increases, the Provenge market is expected to grow.
The expansion of clinical trials is also expected to support the Provenge market's growth. This expansion is driven by advancements in medical research, a higher demand for new treatments, regulatory support, and increasing investments in biotechnology and pharmaceuticals. Clinical trials play a critical role by proving the efficacy and safety of Provenge, which boosts confidence among healthcare providers and encourages more patients to use the treatment. For instance, the Association of the British Pharmaceutical Industry reported that the number of industry-initiated clinical trials in the UK increased from 411 in 2022 to 426 in 2023. As more trials expand, the Provenge market is likely to grow as well.
Rising healthcare expenditure is another factor expected to propel the Provenge market. Healthcare expenditure refers to the financial resources allocated to healthcare services, including personal healthcare, preventive care, and public health programs, all aimed at improving health outcomes. The increase in healthcare spending is driven by an aging population, the prevalence of chronic diseases, advancements in medical technology, rising drug prices, and the growing demand for healthcare services. As healthcare spending increases, broader access to Provenge for advanced prostate cancer treatment is facilitated. For instance, the UK Office for National Statistics reported that total healthcare expenditure grew by 5.6% from 2022 to 2023. Additionally, long-term health and social care expenditure saw a real-term increase of 2.8% in 2022. Consequently, the rise in healthcare spending is expected to further drive the Provenge market.
The key company operating in the provenge market is Dendreon Pharmaceuticals LLC.
North America was the largest region in the provenge market in 2024. The regions covered in provenge report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the provenge market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Provenge (sipuleucel-T) is an autologous cellular immunotherapy used to treat advanced prostate cancer. It works by stimulating the patient's immune system to recognize and attack prostate cancer cells. Provenge is personalized for each patient, utilizing their own immune cells, which are modified and reintroduced to boost their cancer-fighting abilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indication for Provenge is metastatic prostate cancer, including hormone-refractory prostate cancer. Metastatic prostate cancer occurs when the disease spreads beyond the prostate to other parts of the body. Provenge addresses this by enhancing the immune response to target and combat cancer cells. It is distributed through direct sales, pharmaceutical distributors, and online pharmacies, and is used in settings such as hospitals, cancer treatment centers, home care, and other healthcare environments.
The provenge market consists of sales of provenge intravenous infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising geriatric population, increased cancer awareness, growing demand for personalized medicine, rising research and development activities, and government initiatives. Major trends in the forecast period include innovations in immune oncology, combination therapies, product innovation, advancements in vaccine technology, and advancements in technology.
The increasing prevalence of prostate cancer is expected to contribute to the growth of the Provenge market in the coming years. Prostate cancer occurs when cells in the prostate gland begin growing uncontrollably, forming tumors that can spread to nearby tissues or other parts of the body. This rise in cases is linked to factors such as an aging population, better detection techniques, and changes in lifestyle. Provenge works by stimulating the patient's immune system to identify and attack prostate cancer cells. For example, the American Cancer Society estimates that in 2023, there will be 288,300 new cases of prostate cancer and 34,700 related deaths in the United States. As the number of prostate cancer cases increases, the Provenge market is expected to grow.
The expansion of clinical trials is also expected to support the Provenge market's growth. This expansion is driven by advancements in medical research, a higher demand for new treatments, regulatory support, and increasing investments in biotechnology and pharmaceuticals. Clinical trials play a critical role by proving the efficacy and safety of Provenge, which boosts confidence among healthcare providers and encourages more patients to use the treatment. For instance, the Association of the British Pharmaceutical Industry reported that the number of industry-initiated clinical trials in the UK increased from 411 in 2022 to 426 in 2023. As more trials expand, the Provenge market is likely to grow as well.
Rising healthcare expenditure is another factor expected to propel the Provenge market. Healthcare expenditure refers to the financial resources allocated to healthcare services, including personal healthcare, preventive care, and public health programs, all aimed at improving health outcomes. The increase in healthcare spending is driven by an aging population, the prevalence of chronic diseases, advancements in medical technology, rising drug prices, and the growing demand for healthcare services. As healthcare spending increases, broader access to Provenge for advanced prostate cancer treatment is facilitated. For instance, the UK Office for National Statistics reported that total healthcare expenditure grew by 5.6% from 2022 to 2023. Additionally, long-term health and social care expenditure saw a real-term increase of 2.8% in 2022. Consequently, the rise in healthcare spending is expected to further drive the Provenge market.
The key company operating in the provenge market is Dendreon Pharmaceuticals LLC.
North America was the largest region in the provenge market in 2024. The regions covered in provenge report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the provenge market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Provenge (sipuleucel-T) is an autologous cellular immunotherapy used to treat advanced prostate cancer. It works by stimulating the patient's immune system to recognize and attack prostate cancer cells. Provenge is personalized for each patient, utilizing their own immune cells, which are modified and reintroduced to boost their cancer-fighting abilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indication for Provenge is metastatic prostate cancer, including hormone-refractory prostate cancer. Metastatic prostate cancer occurs when the disease spreads beyond the prostate to other parts of the body. Provenge addresses this by enhancing the immune response to target and combat cancer cells. It is distributed through direct sales, pharmaceutical distributors, and online pharmacies, and is used in settings such as hospitals, cancer treatment centers, home care, and other healthcare environments.
The provenge market consists of sales of provenge intravenous infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Provenge Market Characteristics4. Provenge Market Trends And Strategies5. Provenge Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Provenge Pricing Analysis & Forecasts30. Global Provenge Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Provenge Market32. Recent Developments In The Provenge Market
3. Provenge Market Biologic Drug Characteristics
6. Global Provenge Growth Analysis And Strategic Analysis Framework
8. Provenge Market Segmentation
9. Global Provenge Epidemiology Of Clinical Indications
10. Provenge Market Regional And Country Analysis
11. Asia-Pacific Provenge Market
12. China Provenge Market
13. India Provenge Market
14. Japan Provenge Market
15. Australia Provenge Market
16. South Korea Provenge Market
17. Western Europe Provenge Market
18. UK Provenge Market
19. Germany Provenge Market
20. France Provenge Market
21. Eastern Europe Provenge Market
22. North America Provenge Market
23. USA Provenge Market
24. Canada Provenge Market
25. South America Provenge Market
26. Middle East Provenge Market
27. Africa Provenge Market
28. Provenge Market Competitive Landscape And Company Profiles
29. Global Provenge Market Pipeline Analysis
33. Provenge Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Provenge Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on provenge market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for provenge ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The provenge market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Metastatic Prostate Cancer; Hormone Refractory Prostate Cancer2) By Distribution Channels: Direct Sales; Pharmaceutical Distributors; Online Pharmacies
3) By End User: Hospitals; Cancer Treatment Centers; Home Care Settings; Other End Users
Key Companies Profiled: Dendreon Pharmaceuticals LLC
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Dendreon Pharmaceuticals LLC
